MET and breast cancer: The study highlighted that ERBB1 overexpression correlated with high p-c-MET expression [62], substantiating our hypothesis that the co-targeting of ERBB1 and c-MET could be an important therapeutic strategy in the treatment of BC progression and metastasis.